Table 2.
Activity of PHA-848125 as single agent on different human glioma models
| Model | Inoculum | Schedule | No. of mice per group | Treatment start after inoculum | Average tumour weight at start (g) | TGI (measured the day after end of treatment) | MST treated (MST control) |
|---|---|---|---|---|---|---|---|
| U251 | s.c. | 40 mg·kg−1 | 8 | Day 14 | 0.163 | 80% (day 24) | n.a. |
| 1–10 OS bid | |||||||
| U87MG | s.c. | 40 mg·kg−1 | 8 | Day 8 | 0.224 | 71% (day 18) | n.a. |
| 1–10 OS bid | |||||||
| U251 | i.c. 2 × 105 cells per mouse | 40 mg·kg−1 | 9 | Day 1 | 0 | – | 28 (22) |
| 1–10 OS bid | |||||||
| U251 | i.c. 1 × 105 cells per mouse | 40 mg·kg−1 | 9 | Day 15 | 0.003 | 71% (day 35) | 42 (33) |
| 1–20 OS bid |
n.a., not applicable.